## Expert Assessment: STMN2 Splice Switching for ALS-FTD-AD
### Druggability: HIGH
This hypothesis targets a **highly tractable** mechanism. The poison exon inclusion event is straightforward to block with antisense oligonucleotides (ASOs), analogous to the successful nusinersen (Spinraza) approach for SMN2 splicing in SMA. Preclinical data in iPSC-derived neurons demonstrates robust rescue of STMN2 levels and axonal protection upon ASO-mediated exon skipping. Splice-switching ASOs represent well-established platform technology with known pharmacokinetic-pharmacodynamic relationships.
**Specific compounds in development** include ASO candidates targeting the STMN2 splice branchpoint/acceptor site (Biogen/Ionis collaboration). Published preclinical work (Klim et al., 2019; Volvo et al., 2021) establishes the mechanistic proof-of-concept in human neurons.
### Feasibility: MODERATE-HIGH
The mechanism is biologically compelling—TDP-43 loss directly causes STMN2 dysregulation, and stathmin-2 is a validated axonal maintenance factor. However, human validation remains limited. The therapeutic index concern is real: stathmin-2 is a microtubule-destabilizing protein, and constitutive knockdown may impair normal axonal transport. The primary uncertainty is whether STMN2 correction alone is sufficient or whether concurrent TDP-43 functional restoration is needed.
### Competitive Landscape
Multiple players pursue TDP-43 biology: Biogen has active ASO programs (including TDP-43 itself); Ionis has CNS-penetrant ASO platforms; Wave Life Sciences develops small-molecule splicing modulators. STMN2-specific approaches face competition but remain differentiation-worthy if efficacy proves superior to broader TDP-43 strategies.
### Safety Concerns
- **On-target CNS toxicity**: Microtubule dynamics disruption in surviving neurons
- **ASO class effects**: Thrombocytopenia, hepatotoxicity, CSF pleocytosis
- **Delivery limitation**: Intrathecal dosing required; uneven spinal cord distribution
- **Biomarker gap**: No validated pharmacodynamic marker for target engagement in humans
### Timeline Estimate
Phase I readiness: 2-3 years with IND-enabling studies. First-in-human trials likely in ALS (easier enrollment, established endpoints) before FTD-AD expansion. Total development: 6-8 years minimum.
**Verdict**: Mechanistically sound and druggable, but require careful dose-titration to establish therapeutic window before committing to full development program.